Malaria

Infectious Disease·MeSH: Malaria

Prevalence

5.0 / 100K

29 drugs in development·14 companies·13 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
arakoda	60 DEGREES PHARMACEUTICALS, INC. (SXTP)
BinaxNOW® / Panbio® rapid testing platforms	ABBOTT LABORATORIES (ABT)

Phase 2(9)

Phase 1(2)

Drug	Company
BNT165b1	BioNTech SE (BNTX)
malaria vaccine	MYMETICS CORP (MYMX)

Preclinical(5)

Unknown(3)

Drug	Company
BinaxNOW® and Panbio® rapid testing platforms	ABBOTT LABORATORIES (ABT)
cobeter 20/120	Luckwel Pharmaceuticals Inc. (LKYM)
cobeter 80/480	Luckwel Pharmaceuticals Inc. (LKYM)

BLA Filed(1)

Drug	Company
ljpc-0118	LA JOLLA PHARMACEUTICAL CO (LJPC)

Phase 1/Phase 2(1)

Drug	Company
BNT165e	BioNTech SE (BNTX)

Phase 4(6)

Drug	Company
Artemether + Lumefantrine	Crinetics Pharmaceuticals, Inc. (CRNX)
AS-AQ	UNITED THERAPEUTICS Corp (UTHR)
DHP	UNITED THERAPEUTICS Corp (UTHR)
Dihydroartemisinin-piperaquine	Crinetics Pharmaceuticals, Inc. (CRNX)
PfSPZ Vaccine	Cidara Therapeutics, Inc. (CDTX)
Tirzepatide	UNITED THERAPEUTICS Corp (UTHR)

BioSniper tracks 29 drugs in development for Malaria across 14 companies.

There are 13 clinical trials targeting Malaria tracked by BioSniper.

The estimated prevalence of Malaria is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.